Sybron Quietly Builds a Powerhouse
Executive SummarySybron International, hardly a well-known name in the diagnostics industry, has built a $350 million highly profitable diagnostics business by acquiring small, niche companies. Its latest acquisition, Microgenics Corp., makes it an important player in the drugs of abuse and therapeutic drug monitoring businesses. Microgenics had been part of Boehringer Mannheim Corp. But when Roche bought Boehringer Mannheim, the FTC required Roche to sell off Microgenics for anti-trust reasons. Microgenics was sold last summer to an investor group, which sold it to Sybron.
You may also be interested in...
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.
Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug; FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.
FerGene bladder cancer therapy achieved a complete response in more than half of patients in its pivotal trial. The joint venture now looks to commercialization and potential expansion of indications.